Related Experiment Video
Updated: Oct 13, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
[Continuity of utilization of a levonorgestrel releasing contraceptive implant: prospective study in Belgium]
M Vekemans1, A Delvigne, M Paesmans
1Service de Gynécologie-Obstétrique, Centre Hospitalier Universitaire Saint-Pierre, Bruxelles.
Abstract:
Since 1988 we inserted 760 sets of a subcutaneous hormonal contraceptive releasing levonorgestrel active for 5 years. The aim of the study was to investigate the continuation rates. We considered our first 612 insertions. The 5-year cumulative pregnancy rate was 3.7%. The continuation rates were high (50% of the implants remained in situ after 3 1/2 years). These rates increased with age, and were better with European than with non-European subjects (mainly Moroccan and Turkish women). Parity didn't influence. The rates increased over time, because more unhappy women soon came back compared to satisfied users. Removals were related to pregnancy wish, irregular blood loss, end of action, and various side effects. In a few cases untrained physicians removed the implants.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence studies: Biowaivers
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Oral Drug Delivery Systems: Continuous-Release Systems
Intrauterine Drug Delivery Systems